spacer
home > ebr > spring 2009 > rnai therapeutics: promise, speed and challenge
PUBLICATIONS
European Biopharmaceutical Review

RNAi Therapeutics: Promise, Speed and Challenge

 

RNA interference has the potential to one day enable physicians to turn off genes at will using small synthetic RNA molecules, and thus offer new therapies for both acute and chronic diseases, such as cancer and diabetes. The gene sequence based, ‘designer’ nature of these small RNAs allows drug leads to be discovered and optimised faster than ever, and lab-to-clinic speeds have accelerated to unprecedented levels. But there’s a challenging endgame ahead: unlocking safe and effective delivery methods that will enable RNAi and other oligonucleotide therapeutics to realise their full potential.

HIGH EXPECTATIONS

In 2002, the journal Science proclaimed RNAi the ‘breakthrough of the year,’ a declaration that came shortly after the discovery of RNAi in human cells. That advance sparked anticipation that RNAi could be used to silence the genes behind a wide range of devastating conditions – a list that included cancer, metabolic disorders, Huntington’s disease, Alzheimer’s disease and others. Because RNAi therapeutics are based on gene sequence, rather than protein structure, it became clear that any diseasecausing gene was back in play as a pharmaceutical target, regardless of how difficult prior efforts had proved to ‘drug’ the disease-causing protein.

It seems incredible today, but we have known about RNAi for less than two decades. The story of its first observations in 1990 by Rich Jorgensen in the course of his work with petunia pigmentation is already the stuff of folklore within the field. Eight years later, Andrew Fire and Craig Mello at the Carnegie Institution of Washington found the phenomenon was caused by long double-stranded RNA, which triggered the reduced expression of the target gene, a discovery that led to their 2006 Nobel Prize in Physiology or Medicine.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Bob Brown, PhD, is Senior Vice President, Research, at Dicerna Pharmaceuticals, a private, venture-backed RNAi-focused biopharmaceutical company developing novel therapeutic agents in multiple disease areas. Prior to joining Dicerna, Bob was Vice President, Research and Technology at Genta, where he had over 75 issued patents and patent applications. There, Bob became one of the only R&D executives in the biotechnology industry to follow a systemically administered oligonucleotide therapeutic (GenasenseTM) from the research bench, through Phase I, II, and III clinical trials and NDA review. Before joining Genta, Bob was co-founder and VP of Research and Development at Oasis Biosciences. He holds a PhD in Molecular Biology from the University of California, Berkeley, and a BS in both Chemistry and Biology from the University of Washington.

spacer
Bob Brown
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Discussing developments on Highly Potent APIs with industry expert, Richard Arnett for the HPAPI USA conference 2019

Ahead of the 2019 HPAPI USA Conference taking place in Boston on 21st – 22nd October, SMi caught up with Richard Arnett, Manager, Industrial Hygiene, Pharmascience who is speaking on Day Two of the agenda. Richard shared his thoughts on how the industry has developed and briefly touched on what he will be discussing in October.
More info >>

White Papers

Managing GxP Environmental Systems to Ensure Data Integrity

Vaisala Ltd


More info >>

 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement